Open AccessAlpha lipoic acid: A treatment option for diabetic patients with Covid 19
Author(s) -
Hossein Bahrami Moghadam,
Mahmood Maniati
Publication year - 2021
Publication title -
health technology assessment in action
Language(s) - English
Resource type - Journals
ISSN - 2645-3835
DOI - 10.18502/htaa.v4i3.6352
Subject(s) - medicine , alpha lipoic acid , diabetes mellitus , asymptomatic , disease , pneumonia , clinical trial , lipoic acid , intensive care medicine , antioxidant , oxidative stress , endocrinology , biochemistry , chemistry
The new coronavirus pneumonia, which first occurred in China in December 2019, has a wide spectrum of symptoms from asymptomatic to very severe involvement and even death. The main reason for the increase in the severity of this disease is the body's inflammatory response to the virus, and due to the lack of effective antiviral treatment for this disease, it is necessary to take therapeutic interventions to reduce the body's inflammatory response. It is noteworthy that diabetic patients are more severely exposed to this disease and this calls for appropriate treatment to control diabetes in patients with COVID19. In addition to its antioxidant and anti-inflammatory effects, alpha lipoic acid also has therapeutic effects in controlling diabetes and blood sugar. Therefore, it is suggested that clinical trials be performed to evaluate the effects of alpha-lipoic acid on diabetic patients with COVID19